| A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease A Zuiani, CL Dulberger, NS De Silva, M Marquette, YJ Lu, GM Palowitch, ... Cell, 2024 | 4 | 2024 |
| 769 Interim clinical and translational data from NTC-001, a phase I study to evaluate the non-engineered neoantigen-specific T cell product BNT221 in patients with advanced or … JSW Borgers, D Lenkala, B McCarthy, V Kohler, S Hymson, E Jackson, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| 1017O NTC-001: A phase I study to test safety and efficacy of BNT221, a non-engineered neoantigen-specific T cell product, in patients with advanced or metastatic melanoma JSW Borgers, D Lenkala, B McCarthy, V Kohler, S Hymson, K Esaulova, ... Annals of Oncology 34, S619, 2023 | 2 | 2023 |
| The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection CM Arieta, YJ Xie, DA Rothenberg, H Diao, D Harjanto, S Meda, ... Cell 186 (11), 2392-2409. e21, 2023 | 31 | 2023 |
| Coronavirus vaccines and methods of use RB Gaynor, L Srinivasan, A Poran, D Harjanto, C Kuksin, DA Rothenberg, ... US Patent App. 17/912,841, 2023 | 2 | 2023 |
| Coronavirus vaccines and methods of use RB Gaynor, L Srinivasan, A Poran, D Harjanto, C Kuksin, DA Rothenberg, ... US Patent App. 17/481,781, 2023 | 1 | 2023 |
| Coronavirus vaccines and methods of use RB Gaynor, L SRINIVASAN, A PORAN, D HARJANTO, C KUKSIN, ... | | 2023 |
| A universal MHCII technology platform to characterize antigen-specific CD4+ T cells R Vyasamneni, V Kohler, B Karki, G Mahimkar, E Esaulova, J McGee, ... Cell Reports Methods 3 (1), 2023 | 2 | 2023 |
| Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer MM Awad, R Govindan, KN Balogh, DR Spigel, EB Garon, ME Bushway, ... Cancer Cell 40 (9), 1010-1026. e11, 2022 | 73 | 2022 |
| Compositions and methods for preparing t cell compositions and uses thereof R Ang, V Juneja, R Gaynor US Patent App. 17/599,468, 2022 | | 2022 |
| Validation of Predicted Neoantigens in Patient Derived Material by Targeted Mass Spectrometry K Marquart, T Kohler, M Bushway, K Balogh, M Kirsh, MS Rooney, ... Molecular & Cellular Proteomics 21 (8), S48-S48, 2022 | | 2022 |
| Combination therapy with neoantigen vaccine R Ang, R Gaynor, M Goldstein US Patent App. 17/251,285, 2021 | | 2021 |
| 201 BNT221, an autologous neoantigen-specific T-cell product for adoptive cell therapy of metastatic ovarian cancer C Arieta, D Velez, S Hannes, S Meda, B McCarthy, D Lenkala, D Harjanto, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | | 2021 |
| Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations J Choi, SP Goulding, BP Conn, CD McGann, JL Dietze, J Kohler, ... Cell reports methods 1 (5), 2021 | 31 | 2021 |
| Coronavirus vaccines and methods of use RB Gaynor, L SRINIVASAN, A PORAN, D HARJANTO, C KUKSIN, ... | | 2021 |
| A personal neoantigen vaccine NEO-PV-01 in combination with chemotherapy and pembrolizumab induces broad de novo immune responses in first-line non-squamous NSCLC: Associations … MM Awad, R Govindan, DR Spigel, EB Garon, V Kohler, R Vyasamneni, ... Cancer Research 81 (13_Supplement), 73-73, 2021 | 2 | 2021 |
| Defining HLA-II ligand processing and binding rules with mass spectrometry enhances cancer epitope prediction JG Abelin, D Harjanto, M Malloy, P Suri, T Colson, SP Goulding, ... Immunity 54 (2), 388, 2021 | 8 | 2021 |
| Sequence-based prediction of SARS-CoV-2 vaccine targets using a mass spectrometry-based bioinformatics predictor identifies immunogenic T cell epitopes A Poran, D Harjanto, M Malloy, CM Arieta, DA Rothenberg, D Lenkala, ... Genome medicine 12, 1-15, 2020 | 82 | 2020 |
| Combined TCR repertoire profiles and blood cell phenotypes predict melanoma patient response to personalized neoantigen therapy plus anti-PD-1 A Poran, J Scherer, ME Bushway, R Besada, KN Balogh, A Wanamaker, ... Cell Reports Medicine 1 (8), 2020 | 38 | 2020 |
| Abstract PO-015: Systematic discovery of KRAS neoantigens J Choi, SP Goulding, BP Conn, CD McGann, JL Dietze, J Kohler, ... Cancer Research 80 (22_Supplement), PO-015-PO-015, 2020 | | 2020 |
